If you would like to be added to the mailing list to receive this newsletter, please contact: Kentucky Diabetes Connection,

P.O. Box 309, Owensboro, KY 42302-0309 or Phone: 270-686-7747 ext.: 3031 or Email: janice.haile@ky.gov.

Fourth Quarter 2016

Notice: The printing and mailing of this issue was delayed.

Ohio River Regional Chapter

LEADERS ADDRESS THE

KENTUCKY DIABETES NETWORK

Dr. Hiram Polk, pictured at left,

Commissioner of the Kentucky Department

for Public Health and Charles Kendell,

pictured on the right, an independent

consultant and former chief of staff with the

Kentucky Department for Public Health,

presented at the Kentucky Diabetes Network

(KDN) meeting held December2nd at the

Kentucky History Center in Frankfort.

Hiram Polk, MD, Commissioner of the

Kentucky Department for Public Health,

addressed diabetes professionals and

advocates at the Kentucky Diabetes

Network (KDN) meeting held December

2nd at the Kentucky History Center in

Frankfort. Dr. Polk noted that

addressing diabetes and prediabetes are

public health priorities and that reaching

more Kentuckians to improve their

health is important. Dr. Polk said that as

a surgeon he saw first-hand the

ravages of diabetes and how critical

prevention efforts — such as foot

examinations — continue to be.

Charles Kendell, an independent

consultant and former chief of staff with

the Kentucky Department for Public

Health, also addressed KDN by giving an

overview of how a bill becomes a law and

differences in lobbying versus education.

Mr. Kendell summarized the recent

legislative changes in Frankfort and

stressed the need to “educate and become a

resource” especially for new legislators.

Lastly, Mr. Kendell shared a link whereby

a person can sign-up to follow Kentucky

legislation — http://kentucky.gov/services/

pages/billwatch.aspx.

2

A NEW Kentucky Diabetes TRENDS column will begin to be featured ongoing as part of this publication.

Data and charts will be taken from the Centers for Disease Control and Prevention (CDC),

Behavioral Risk Factor Surveillance System (BRFSS).

Kentucky diabetes trend data may be used by organizations across the state to identify strengths and weaknesses. The data may

then be utilized to set goals for improving diabetes care practices in Kentucky. Watch future newsletters for the continued series.

KY DIABETES TRENDS IN CARE PREVENTIVE CARE PRACTICES

HEALTH PROFESSIONAL VISIT FOR DIABETES

To access the complete data for cumulative years shown in graph: https://gis.cdc.gov/grasp/diabetes/diabetesatlas.html#.

ATTENDED DIABETES SELF-MANAGEMENT CLASS

To access the complete data for cumulative years shown in graph: https://gis.cdc.gov/grasp/diabetes/diabetesatlas.html#.

Age-Adjusted Percentage, Adults With Diabetes

Year Percentage

2003 92.8%

2004 93.3%

2005 92.5%

2006 90.7%

2007 87.4%

2008 92.6%

2009 88.8%

2010 85.9%

2011 87.6%

2012 84.1%

2013 87.5%

2014 *

*Indicates “No Data”

Vertical dotted line indicates major changes made to the survey methods in 2011. Horizontal dotted line indicates “No Data”, “Suppressed Data”, or both.

Vertical dotted line indicates major changes made to the survey methods in 2011. Horizontal dotted line indicates “No Data”, “Suppressed Data”, or both.

Age-Adjusted Percentage Adults — Total

Year Percentage

2003 46.8%

2004 54.8%

2005 51.6%

2006 54.3%

2007 51.7%

2008 47.5%

2009 52.2%

2010 58.0%

2011 45.7%

2012 50.5%

2013 54.4%

2014 *

*Indicates “No Data”

87.5 % adult

Kentuckians

with

Diabetes

report

visiting a

health

professional

for diabetes

in the last

year (2013).

Just a little

over half

(54.4%)

adult

Kentuckians

with

Diabetes

report ever

attending a

diabetes self–

management

class (2013).

3

Photo at Left

Governor Bevin Signed

a Diabetes Proclamation

in November for National

Diabetes Month.

To view the Proclamation:

http://apps.sos.ky.gov/

Executive/Journal/

execjournalimages/2016-

PROC-247006.pdf

DIABETES MONTH AROUND

KENTUCKY Photo at Left

A group of diabetes

professionals and

advocates attended

the Health and

Welfare Interim Joint

Committee legislative

meeting on October

19, 2016, where Bob

Babbage presented

an “Update on

Diabetes in

Kentucky”.

Attendees at the

meeting, pictured left

to right, were Mary

Beth Lacy, Becki

Thompson, Diana

Reed, Reita Jones,

Kim DeCoste, Dr.

Joseph Loftus,

Theresa Renn,

Stewart Perry, Bob

Babbage, Jim

DeMasters

Julie Babbage and

Gary Dougherty.

COURIER-JOURNAL

DIABETES SERIES WAVE 3 TV

DIABETES EDITORIAL WAVE 3 TV (Louisville) General Manager, Ken Selvaggi,

aired a diabetes editorial entitled, Dealing With Diabetes.

To view the video, visit: http://www.wave3.com/

story/33847921/wave-3-news-editorial-december-1-2016-

dealing-with-diabetes.

Photo at Right

University of Kentucky

Memorial Hall was lit

up blue in recognition of

World Diabetes Day

on November 14th.

In November, the Louisville Courier-Journal printed an

intensive series of diabetes / prediabetes articles, listed below,

and an opinion piece by Bob Babbage and Stewart Perry.

11-13-16 Disease A State Scourge Silent Killer Ranks 6th Worst in US

Teen Adjusts to Type 2 Diabetes

11-14-16 Bedeviling “Diabetes Belt” Diabetes Remains on Rise Despite Efforts in KY, IN Prediabetes Signals Need to Change Lifestyle Habits

11-20-16 Diabetic’s Diagnosis: Lose His Leg or His Life Disease Complications are Leading Cause of Non-injury

Amputations

Medicaid Changes Could Affect Diabetes Care

11-21-16 Going Vegan, Reluctantly

But A New Diet is Part of Life Changes for Diabetics

Reds All-Star is Powering Through Type 1 Diabetes

To read the complete series of articles, go to:

http://www.courier-journal.com/story/life/wellness/

health/2016/11/18/diabetes-kentuckys-epidemic/94070310/ .

4

DIABETES MONTH AROUND KENTUCKY (CONTINUED)

Lake Cumberland District

Photo at Right: McCreary County

Judge Douglas Stephens,

pictured on the left, holds

up a diabetes

proclamation with Vicky

Albertson, RN, pictured

on the right.

Photo at Right: Clinton County

Judge Richard Armstrong,

pictured on the left, holds up a

diabetes education packet with

Vicky Albertson, RN, pictured

on the right.

Photo at Left: Green County

Judge John Frank,

pictured on the left, signed

a diabetes proclamation in

recognition of World

Diabetes Day on November

14th with Janet Cowherd,

RN, BSN, pictured on the

right.

Photo at Left: Cumberland County

Judge John Phelps, Jr.,

pictured on the right, signed a

diabetes proclamation

recognizing diabetes month

with Vicky Albertson, RN,

pictured on the left.

Photo at Right: Casey County

Judge Randy Dial, pictured

on the right, signed a

diabetes proclamation while

Janet Cowherd, RN, BSN,

pictured on the left,

looks on.

Photo at Left: Adair County

Judge Mike Stephens,

pictured on the left, signed a

diabetes proclamation during

diabetes month in November

with diabetes educator Jamie

Lee, RN, CDE, MLDE,

pictured on the right.

November 14th was declared Diabetes Awareness Day across the entire Lake

Cumberland District as all ten County Judge Executives signed proclamations to

increase awareness of diabetes as well as support for those living with diabetes.

5

Pulaski County Judge Steve Kelley, pictured on the right, smiles

after signing a diabetes proclamation during diabetes month

with Jamie Lee, RN, CDE, MLDE.

Photo at Right: Wayne County Judge Mike Anderson,

pictured above on the right, smiles as he

prepared to sign the 2016 Diabetes

Proclamation with Vicky Albertson, RN,

pictured above on the left.

Russell County Judge Gary Robertson,

pictured above on the right, signed a

diabetes proclamation while Jamie Lee,

RN, CDE, MLDE, pictured above left,

looks on. Photo at Left: Taylor County Judge Eddie Rogers,

pictured above on the left, after he

signed the diabetes proclamation

with Janet Cowherd, RN, BSN,

pictured on the right.

DIABETES MONTH AROUND KENTUCKY (CONTINUED)

NEW MY DIABETES CARE RECORD NEW

Download or order this

item from KDN at:

http://

www.kydiabetes.net/

kdncontinuousqualityim

provementtoolkit.html

Available Soon!

My Diabetes Care Record

The My Diabetes Care Record will soon be available on the

Kentucky Diabetes Network (KDN) website to download or

order. Up to 50 cards can be ordered directly without charge

from KDN.

This card can be used to teach patients about their Diabetes

ABCs — A1C, Blood Pressure, Cholesterol, Stop Smoking and

Self-Management Education. The card can also be used to

encourage other important recommended tests and exams. This

card folds up small enough to fit in a wallet.

Diabetes Proclamation Sample

used in Lake Cumberland

shown below.

6

KENTUCKY STATEWIDE DIABETES

SYMPOSIUM

Susan Weiner, MS, RDN, CDE, CDN, pictured at left, the

2015 AADE Diabetes Educator of the Year (from Bellmore, NY) and

Tom Karlya, BA, pictured at right, the Vice President of the Diabetes Research Institute Foundation, Inc.

(from Surfside Beach, SC) jointly presented

“Type 1 Diabetes — The Missing Diagnosis”.

Tina Claypool, PharmD, CDE, pictured at left,

with KentuckyOne Health, University of Louisville

Hospital Outpatient Pharmacy (from Louisville, KY)

presented “New Diabetes Medications: Provider Pearls

AND Medication Therapy Management (MTM) in

Diabetes”.

Jenny Marshall-Willis, APRN, CDE, CPT, pictured at left, with

Kosair Children's Hospital, Maternal - Fetal Medicine Specialists

Louisville, KY and Molly Houser, MD, FACOG, CDE, pictured at

right, formerly with Baptist Health Lexington

jointly presented

“Diabetes and High Risk Pregnancies: Improving Outcomes”.

Shubham Gupta, MD, pictured at

left, Assistant Professor of

Urology with the

University of Kentucky,

Lexington, KY presented

“Sexual Health in Diabetes”.

Larry A. Watson, Certified

Coach, BS, pictured at right,

with Pathway Consulting from

Cincinnati, OH presented

“Diabetes Care Professional:

Optimizing Performance to

Enhance Patient Outcomes”.

The KY Statewide Diabetes Symposium 2016 boasted

attendance of 361 professionals. The breakdown of

participants included professionals from KY, IN, IL,

TN, OH, and AZ (Nurses 139 [of this number 110 RN,

26 APRN, 3 LPN]; Dietitians / RDs 106; Pharmacists

51 [of this number 42 Pharm D, 9 RPh ]; Diabetes

Paraprofessionals 12; LCSW (Social Workers) 4;

MD 4; Diabetes Camp Leaders 2; ADA Leader 1;

Certified Nutritionist 1; KY Employees Health Plan

Leader 1; Photographer 1; Speakers (not counted

elsewhere) 2; Exhibitors (not counted elsewhere) 37.

The KY Statewide Diabetes Symposium 2016 was Held on November 4th in

Recognition of World Diabetes Day at the Marriott Louisville East.

7

The Kentucky Statewide Diabetes Symposium committee presented the 2016 Industry Allies Council members with an appreciation award. In photo

above, pictured left to right are Alex Horn with Boston Scientific, Dr. Joseph Loftus with Novo Nordisk, Brandy McDaniel with Novo Nordisk, Jim

DeMasters with Novo Nordisk, Stacy Koch, State Symposium Exhibitor Coordinator and Julie Shapero, State Symposium 2016 Chairperson.

Symposium Photos Courtesy of:

O'Neil Arnold Photography, Louisville, KY

DIABETES SYMPOSIUM (CONTINUED)

Symposium attendees shown above visiting exhibits. Exhibitors

included: Abbott Diabetes Care, ACON Laboratories Inc, Animas

Corporation (Johnson & Johnson), Anthem BCBS, AstraZeneca

Pharmaceuticals, Boehringer Ingelheim, Boston Scientific, CCS

Medical, CinSulin, Dexcom Inc, Dialysis Clinic Inc, Eli Lilly,

Humana CareSource, Janssen, Kroger, Medtronic, Meijer, Merck,

Novo Nordisk, Omnipod, Premier Kids Care, Sanofi, Spectra Mental

Healthcare, Tandem Diabetes Care and Valeritas.

Symposium Committee 2016

Symposium committee members pictured left to right, front row: Teresa

Bunch, Stacy Koch, Barb Jolly, Julie Shapero, Dee Deakins Sawyer,

Janice Haile, and Cathy McCormick. Second row: Deanna Leonard,

Ann Ingle, Betty Bryan, Mechelle Coble, Merritt Bates-Thomas, Theresa

Renn, Janey Wendschlag, Unknown, Maggie Beville, and Dana Graves.

Kentucky Diabetes Symposium 2016 Partners (alphabetical order)

American Association of Diabetes Educators KY Coordinating Body

American Diabetes Association (ADA)

Diabetes Educators of the Cincinnati Area (DECA)

Greater Louisville Association of Diabetes Educators (GLADE)

Juvenile Diabetes Research Foundation (JDRF)

Kentucky Association of Diabetes Educators (KADE)

Kentucky Diabetes Network (KDN)

Kentucky Diabetes Prevention and Control Program (KDPCP)

Tri-State Association of Diabetes Educators (TRADE)

Mark Your Calendar!

Kentucky Statewide

Diabetes Symposium 2017

November 3rd

Industry Allies Council Silver - Novo Nordisk Inc Bronze – Boston Scientific

8

It is hard to believe another year has gone by

and we are looking forward to a year of new

leadership for the Kentucky Coordinating

Body (KY CB). It was such a pleasure

working with those who represent your Local

Networking Groups (LNGs). This included

Maggie Beville, Betty Bryan and Vanessa

Paddy from GLADE; Janey Wendschlag and

Dee Deakins Sawyer from KADE; Janice

Haile, Teresia Huddleston, and Kelly Dawes

from TRADE; as well as Julie Shapero from

DECA.

It is my pleasure to announce the 2017 CB

Leaders: 2017 Leader – Maggie Beville RN, BSN, CDE, MLDE

(GLADE – Greater Louisville Association of Diabetes

Educators)

2018 Leader Elect – Merritt Bates-Thomas RD, CDE (TRADE

– Tri State Association of Diabetes Educators)

Financial Leader – Betty Bryan RN, CDE, MLDE (GLADE);

Dee Deakins Sawyer MS, RN, CDE, BC-ADM (KADE –

Kentucky Association of Diabetes Educators)

Web Administrator – Janice Haile RN, CDE (TRADE)

State Advocacy Grassroots Coordinators – Maggie Beville

and Betty Bryan

Member at Large – Julie Shapero RD, CDE (DECA – Diabetes

Educators of Cincinnati Area)

I have to admit that the Kentucky LNG (Local Networking Group)

Leaders are certainly an awesome group with whom to work. Those

2016 Leaders and members and the LNGs they represent are:

KADE – Janey Wendschlag (Leader), Dee Deakins Sawyer, Ava

Eaves

GLADE – Vanessa Paddy, Ronda Merryman-Valiyi

TRADE – Kelly Dawes (Leader), Deanna Leonard, Teresia

Huddleston

The bimonthly KY CB conference calls with a couple of face-to-

face meetings went well this year. Some of the discussions included

the following:

LNG leaders report during each KY CB call — and I can say we

all have very active groups. GLADE, KADE and TRADE all

have meetings that occur 4 to 6 times per year. KADE’s all day

continuing education (CE) diabetes program was offered in May

and TRADE had an all day program in September. These CE

programs, along with the state diabetes symposium, provide the

needed continuing education for Certified Diabetes Educators

(CDEs) to maintain their certification.

Licensed Diabetes Educators (LDE) – the KY CB had several

discussions around needed guidelines to help professionals who

want to become licensed diabetes educators. A sub-committee

has been created for guideline development and includes Janey

Wendschlag, Maggie Beville and Dana Graves. A draft of

recommendations will be created and sent for the KY CB to

KENTUCKY COORDINATING BODY (CB)

DECA ▬ DIABETES EDUCATORS CINCINNATI AREA ● GLADE ▬ GREATER LOUISVILLE ASSOCIATION OF DIABETES EDUCATORS

KADE ▬ KY ASSOCIATION OF DIABETES EDUCATORS ● TRADE ▬ TRI-STATE ASSOCIATION OF DIABETES EDUCATORS

Submitted by: Dana Graves, RN, MSN, CDE, MLDE, KY, Coordinating Body (CB) Leader

Dana Graves

2016 KY CB Leader

NEW EDITION!

THE ART AND SCIENCE OF

DIABETES SELF-MANAGEMENT

EDUCATION DESK REFERENCE

The American

Association of

Diabetes Educators

(AADE) recently

released the NEW

EDITION of “The Art

and Science of

Diabetes Self-

Management

Education Desk

Reference”.

Order at:

https://www.diabeteseducator.org/online-store

review. I have to thank Vanessa Paddy and Betty Bryan for

keeping us informed about the overall licensure progress!

Diabetes Advocacy has been led by Betty Bryan and Maggie

Beville. The KY CB is hoping to work with the KY Diabetes

Network to organize a “Diabetes Day at the Capitol” with our

legislators in early 2017. We are also collecting stories from

people with diabetes to share with the legislators.

Maggie Beville and Diane Ballard (representing Merritt) will

be attending the annual AADE Coordinating Body (CB)

Leaders meeting in Chicago in early January. Diane Ballard

(from KADE) will be the KY CB 2018 Leader Elect.

A KY CB policy is being developed to help explain and guide

the KY CB. Once completed, it will be shared with members of

each LNG.

A list of new Kentucky AADE members was sent out monthly

by AADE. These members received a “Welcome Letter” from

their respective LNG Leader.

The KY CB group does well to represent the diabetes educators

throughout Kentucky. I highly recommend for each diabetes

educator to get involved with the LNG that is closest to you. The

LNGs provide networking and professional growth at each meeting

(and of course at times great food!!!). When you join AADE, you

choose the LNG you want to be involved in.

I certainly enjoyed this year as the KY CB Leader and I look

forward to 2017 with Maggie at the helm! I believe this year will be

awesome and hope each of you will plan to get involved!

9

We all know that insulin is

not just a drug — for people

with diabetes it is literally a

matter of life and death.

Due to the skyrocketing costs of insulin,

some people have been rationing their

insulin, and others have been going

without other necessities to pay for it. This tragedy strikes at the

heart of our mission. That’s why the American Diabetes

Association’s Board of Directors recently passed a resolution and

we launched a petition calling for immediate action to make insulin

affordable for everyone who needs this lifesaving medication.

Specifically, the Association is requesting for all entities in the

insulin supply chain to increase transparency and to ensure that no

person with diabetes is denied affordable access to insulin. We are

also calling for Congress to hold hearings with all entities in the

insulin supply chain to identify the reasons for the dramatic

increases in insulin prices and to take action to ensure that all

people who use insulin have affordable access to it.

At this writing, the petition has garnered more than 135,000

signatures and is growing every day. Our social media posts about

the petition have been our most successful posts of all time.

The petition continues to pick up speed, but we need help to keep

the momentum going. Please help us ask everyone in the diabetes

community and the general public to lend their voices to this effort

and sign our petition at StopDiabetes.com/insulin. Please share the

petition with your networks, colleagues, friends, family and

neighbors.

This is an important effort for the diabetes community - one that the

Association will continue to work on throughout the coming weeks

and months.

ADA LAUNCHES

INSULIN AFFORDABILITY CAMPAIGN

Gary Dougherty

Submitted by: Gary Dougherty, Director-State

Government Affairs, American Diabetes

Association (ADA). The Board of Directors for the American Diabetes

Association released the following resolution:

WHEREAS, people with diabetes who use insulin need this

medication every day of their lives in order to live;

WHEREAS, health care providers work with people who use

insulin to determine the types and quantities of insulin necessary

to successfully manage their diabetes and to reduce long- and

short-term health consequences, including blindness, amputation,

kidney failure, heart attack, stroke, and death;

WHEREAS, the annual cost of diabetes, gestational diabetes

and prediabetes in the United States skyrocketed to $322 billion

in 2012, a 48 percent increase in just five years;

WHEREAS, the cost of insulin has risen steadily and steeply,

creating financial hardships for individuals who rely on it to

survive, particularly those who are uninsured or underinsured;

WHEREAS, between 2002 and 2013 the average price of insulin

nearly tripled;

WHEREAS, insulin is frequently cited as one of the most

expensive categories of drugs by private and government health

care payers, with insulin leading the list of price hikes for non-

generic drugs in a recent government report on Medicare

spending;

WHEREAS, insulin pricing is driven by a complex supply chain

consisting of many players including manufacturers, wholesalers,

pharmacy benefit managers (PBMs), insurers and pharmacies;

WHEREAS, in much of Europe, insulin costs about a sixth of

what it does in the United States;

WHEREAS, the increased cost of insulin has resulted in a

growing number of people with diabetes telling their health care

providers they are unable to afford the insulin prescribed for

them, thus exposing them to serious long and short term health

consequences; and

Therefore I join with the American Diabetes Association and:

Call upon all entities in the insulin supply chain, including

manufacturers, wholesalers, PBMs, insurers and pharmacies

to substantially increase transparency in pricing associated

with delivery of insulin to the end user patient;

Call upon all entities in the insulin supply chain to ensure that

no person with diabetes is denied affordable access to insulin;

and

Call upon Congress to hold hearings with all entities in the

insulin supply chain to identify the reasons for the dramatic

increases in insulin prices and to take action to ensure that all

people who use insulin have affordable access to the insulin

they need.

10

Submitted by: Tina Claypool, PharmD, CDE

KentuckyOne Health/University Hospital,

Louisville, KY

New Insulin Therapy:

Basaglar® (insulin

glargine injection) U-100

Millions of patients living with diabetes

have new medication therapy and device

options available. As additional new and

complex therapies emerge, it is important

that prescribers, pharmacists, and diabetes educators remain current

with products and formulations to help patients achieve safe and

effective glycemic control. Basaglar® is the first biosimilar insulin

and was approved for use in the European market September 2014.

Basaglar® is expected to enter the United States (US) market, mid-

December of 2016.

Biosimilar Facts: To date, the US Food and

Drug Administration

(FDA) has approved only

four biosimilar

medications since the first

biosimilar was approved in

2015. The European

Medicines Agency (EMA)

has approved seven

biosimilar medications

since 2006 with several

more in clinical trials.

Biosimilars are

medications that contain

an active medication substance that is derived from or composed

of a living organism highly similar to an existing biologic already

approved by the FDA, also known as the “reference product”.

Biosimilar medications must exhibit no clinically meaningful

differences in quality, safety, and efficacy from the reference

product. It is important to understand that biosimilars are NOT

considered generic medications, because they are not chemically

manufactured.

Although the FDA classifies biologic interchangeability, it is US

state laws that govern drug substitution processes. Pharmacists may

NOT substitute a biosimilar product unless the FDA has ruled that

biosimilar to be interchangeable and permits pharmacy substitution

for the reference product. Otherwise, prescribers must write the

specific name of the biosimilar product on the prescription or order.

The goal of biosimilar medications is to improve patient medication

access by offering more affordable medication options without

compromising quality, safety, and efficacy. Biosimilars typically

cost significantly less than their reference products and are projected

to greatly reduce future health care spending.

Basaglar® Dosing: Basaglar® is a new biosimilar long-acting insulin with the same

amino acid sequence as its reference product, Lantus® (insulin

glargine injection). Basaglar® is indicated to improve glycemic

control in adult and pediatric patients with type 1 diabetes mellitus

and in adults with type 2 diabetes mellitus. It is to be administered

subcutaneously once daily at the same time each day. Basaglar® is

contraindicated during episodes of hypoglycemia and in patients

hypersensitive to insulin glargine or any of its excipients. It is not

recommended for treatment of diabetic ketoacidosis.

Basaglar® will be available in a disposable prefilled insulin pen,

KwikPen®, that contains 100 units/mL of insulin glargine per 3 mL

device. The maximum dose per injection is 80 units, thus requiring

more than one injection for doses greater than 80 units.

The recommended starting dose of Basaglar® in patients with type 1

diabetes should be approximately one-third of total daily insulin

requirements, with short or rapid-acting insulin used for meal-time

coverage. The recommended starting dose of Basaglar® in patients

with type 2 diabetes is 0.2

units/kg or up to 10 units SQ

once daily. If changing from

another insulin glargine 100

units/mL product to

Basaglar®, the Basaglar®

dose should be the same as

the other insulin glargine

product. If changing from

once daily insulin glargine

300 units/mL or twice daily

NPH insulin to Basaglar®,

the recommended initial

Basaglar® dosage should be

80% of the insulin glargine

300 units/mL or twice daily

NPH insulin. If changing

from an intermediate or long-acting basal insulin other than insulin

glargine 100 units/mL to Basaglar®, a change in the dose of the basal

insulin, shorter acting insulin, and any blood glucose lowering

medications may need to be adjusted. Increased frequency of blood

glucose monitoring is always recommended when changing insulin

therapies.

Storage: Basaglar® insulin pens are stable up to 28 days after first use. New

pens are to be refrigerated between 36-48ºF. It is recommended that

pens are kept at room temperature for at least 1 hour prior to first

injection and remain at room temperature until empty or expired (28

days). Patients should complete a “safety test” or “pen needle

prime” prior to each injection to ensure they receive the correct

insulin dose and that the pen and needle are working properly. Pens

are to be stored with the pen cap on and not with pen needles

attached. Basaglar® may be injected subcutaneously in the upper

arms, stomach, and thighs. The injection button should be held in

during injection and for an additional five seconds before releasing

the injection button and removing the needle from the skin.

New Insulin Therapy: Basaglar

Tina Claypool

11

Warnings and Precautions: Basaglar® KwikPens® should never be shared between patients,

even if the needle is changed. Sharing Basaglar® increases the risk

for transmission of blood-borne diseases.

Hyperglycemia or hypoglycemia are possible with any changes in

insulin strength, manufacturer, type, or administration method.

Patients should increase blood glucose monitoring and only make

insulin dose changes under close medical attention.

Side Effects: The most common side effect of any insulin, including Basaglar®,

is hypoglycemia, which can be life threatening. Careful monitoring

of blood glucose levels is critical to avoid hypoglycemic events.

Other common adverse reactions associated with Basaglar® include

hypersensitivity and allergic reactions, injection site reactions,

hypokalemia, fluid retention, and weight gain.

As with other insulin, concomitant use of thiazolidinediones can

result in dose-related fluid retention which can lead to or exacerbate

heart failure. Patients should be advised to notify their provider if

they experience swelling or weight gain while taking Basaglar® in

combination with a thiazolidinedione.

Drug Interactions: Drugs that may increase the risk of hypoglycemia:

Antidiabetic medications, ACE inhibitors, angiotensin II

receptor blockers, disopyramide, fibrates, fluoxetine,

monoamine oxidase inhibitors, pentoxifylline, pramlintide,

propoxyphene, salicylates, somatostatin analogs, and

sulfonamide antibiotics

Drugs that may decrease Basaglar® blood glucose

lowering effect:

Atypical antipsychotics, corticosteroids, danazol, diuretics,

estrogens, glucagon, isoniazid, niacin, oral contraceptives,

phenothiazines, progestogens, protease inhibitors,

somatropin, sympathomimetics, and thyroid hormones

Drugs that may increase or decrease blood glucose

lowering effect of Basaglar®:

Alcohol, beta-blockers, clonidine, lithium, pentamidine

(hyperglycemia may follow)

Drugs that may blunt hypoglycemia signs and symptoms:

Beta-blockers, clonidine, guanethidine, and reserpine

Clinical Trials: The ELEMENT 2 clinical study is a 24-week phase 3, randomized,

double-blind trial in 756 adults with type 2 diabetes who were

either insulin-naïve and uncontrolled on 2 or more oral antidiabetic

medications or on Lantus® products along with 2 or more oral

antidiabetic medications with adequate or inadequate control.

Results: 1. There was no statistically significant A1C lowering of

Basaglar® vs. Lantus® products

• Both Basaglar® and Lantus® products reduced A1C by

1.3% at 24 weeks

2. Similar percentage of patients achieved A1C <7% at 24 weeks

• 48.8% patients taking Basaglar® achieved A1C <7%

• 52.5% patients taking Lantus® products achieved A1C

<7%

3. Similar incidence of patients experienced severe symptomatic

hypoglycemia*

• *Defined as an event with symptoms consistent with

hypoglycemia that required assistance of another person

and was associated with either blood glucose <50 mg/dL

or prompt recovery after oral carbohydrate, IV glucose, or

glucagon administration

• <1% patients taking Basaglar® experienced severe

symptomatic hypoglycemia over 24 weeks

• <1 % patients taking Lantus® products experienced

severe symptomatic hypoglycemia over 24 weeks

4. Similar adverse reaction reporting for both Basaglar® vs.

Lantus® products

• Infection was reported in 17% patients taking Basaglar®

and 16% patients taking Lantus® products

• Nasopharyngitis was reported in 6% of patients taking

Basaglar® and 6% patients taking Lantus® products

• Upper respiratory tract infection was reported in 5%

patients taking Basaglar® and 4% patients taking Lantus®

products

Medication errors have been reported when other insulin products

have been accidentally administered instead of insulin glargine.

With more insulin products, concentrations, and formulations

available than ever before, it is extremely important to remind

patients, providers, and caregivers to always verify the insulin label

before each injection.

Basaglar® and Basaglar® KwikPen® are trademarks of Eli Lilly and

Company.

References: Basaglar® (insulin glargine injection) full prescribing information

BASKP-0002-USPI-20160617. Indianapolis, IN: Eli Lilly and

Company.

8 Things to Know About Biosimilars. Medscape. Nov 23, 2016.

Rosenstock J, Hollander P, Bhargava A et al. Similar efficacy and

safety of LY2963016 insulin glargine and insulin glargine

(Lantus®) in patients with type 2 diabetes who were insulin-naïve or

previously treated with insulin glargine: a randomized, double-blind

controlled trial (ELEMENT 2 study). Diabetes, Obesity and

Metabolism 17: 734-741, 2015.

New Insulin Therapy (Continued)

12

MENTAL HEALTH AND DIABETES MAKING APPROPRIATE REFERRALS

Many studies have documented the detrimental effects of depression

in diabetes care. Non-adherence, increased severe catastrophic

health events, and early mortality have all been associated with the

effect of depression. However, less understood is how

psychotherapy can assist with better glycemic control as measured

through A1C reduction1.

Diabetes appears to have a unique relationship to depression when

compared to other chronic illness. Chronic illnesses such as COPD,

CVA, chronic pain, or unregulated blood pressure all improve with

adequate psychotherapy interventions. However, none of these other

chronic illnesses require the same level of intense self care as

diabetes.

This writing is not intended to be a complete

synthesis of the research but rather a

practical guide for clinicians.

This article will attempt to synthesize evidence that

supports: 1. Psychotherapy as an effective tool to assist People With Diabetes

(PWD) in increasing treatment adherence & achieving better

outcomes,

2. Appropriate empirically based tools for making referral

decisions, and

3. Some techniques to facilitate patient referral follow-through.

To date, psychotherapy interventions have focused mostly on

depression outcomes and glycemic control as a dependent variable

of Cognitive Behavioral Therapy (CBT) as routinely practiced and

generally effective at remitting depression.

There is robust evidence that CBT works to decrease depression in

PWD. When the intervention is designed for adherence and

delivered by mental health professionals trained in health

psychology, treatment adherence increases and A1C significantly

improves. Cognitive Behavioral Therapy for Adherence and

Depression (CBT-AD) and similar approaches have been

documented to be more effective than usual care.2.

The American Diabetes Association (ADA) recommends screening

at least every six months for clinical depression. Although at any

given time at least 25% of those with diabetes will be suffering from

depression, psychotherapists and mental health professionals are

poorly utilized for PWD.

What Is The Missing Link? We have all heard, and most of us are guilty of, venting about

adherence issues. The conversation goes something like this. “I told

them what they need to do. I explained the consequences of not

changing their behavior. Yet when they come back they are still

doing the same old thing that got them into trouble. I've done my

job!“

Further, there is increased pressure on the provider to learn new skill

sets that are widely known to increase the length of a consult. A

common technique is motivational interviewing. In health

psychology we call it giving hope. Health psychology is the missing

link. Many studies document this but referrals seem to lag behind

what the research would indicate is appropriate.

As clinicians we have all been affected by the increased demands

for better outcomes, the need to see more people in less time, and

pay for performance. Appropriate psychotherapy decreases A1C, a

concrete measure of outcomes. The patient is less likely to perceive

the clinician as the “diabetes police”, which decreases no-shows.

The time needed for an appointment is decreased as there are fewer

complications to review.

Empirical Evidence Supporting Better

Diabetes Outcomes and Psychotherapy;

Cognitive Behavioral Therapy for Adherence

and Depression (CBT-AD) with uncontrolled

T2, Life-Steps 3

Much written about the effective treatment of depression in diabetes

care without corresponding improvement in glycemic control, which

is beyond the focus of this article. As published in Diabetes Care on

CBT-AD4, researchers found robust results when compared to an

enhanced treatment as usual (ETAU) control group.

The Enhanced Treatment as Usual (ETAU) & CBT-

AD groups received the following: 1. A nurse diabetes educator for diabetes self-management

education to tailor goals for self-care.

2. Meetings with a dietitian for nutritional assessment and goal

setting.

3. One session of Life Steps (CBT-AD) a stand-alone CBT

intervention designed to improve adherence to medical

recommendations.

Karl Bates, LCSW

Watch future issues of this newsletter for the continued

Mental Health and Diabetes series..

Submitted by: Karl Bates, LCSW, Spectra Mental Healthcare, Louisville, KY

WHY REFER, WHEN TO

REFER, WHO TO

REFER TO, & HOW TO

SUCCESSFULLY REFER

13

The American Diabetes Association

(ADA) recently published the

Standards of Medical Care in

Diabetes 2017.

ADA STANDARDS OF

CARE 2017

CAMP HENDON JULY 2-7 — REGISTER NOW

Camp Hendon: Taking on Type 1 Diabetes

http://www.camphendon.org/

This fun, safe, and medically-supervised camp is for children

with type 1 diabetes in Kentucky, Southern Indiana and the

surrounding area. The camping experience offers quality

diabetes management education to children ages 8 - 17.

Registration is now open for campers at: https://

hendon.campintouch.com/ui/forms/application/camper/App

Registration is now open for volunteer staff at: https://

hendon.campintouch.com/ui/forms/application/staff/App

View the full

Standards at:

http://

professional.diabetes.

org/sites/

professional.diabetes.

org/files/media/

dc_40_s1_final.pdf.

4. The Montgomery-Asberg Depression Scale and a clinical

interview, administered by a masters or doctoral level

psychologist.

5. The depression assessment results were sent to the participant's

physician with instructions to treat as if patient was not in a

study.

The CBT-AD experimental intervention group received the above

treatments as did the ETAU group. However, the experimental

group also participated in CBT-AD, delivered across 9-12 sessions,

which included educating the patient to the nature of CBT and

motivational interviewing for behavior change. Although the 9 - 12

session protocol is less than usual for depression treatment, a

positive result was obtained. Table 1 shows that the CBT-AD groups

sustained more of the gains made over ETAU during the 12 month

study.

Table 1: CBT-AD Superior to ETAU at

12 Month Follow-up 2013 American Diabetes Association. Published online6

There are only a few other studies that have examined both

psychotherapy, CBT, and treatment adherence, the content, using

specific psychological training material focused on disease treatment

adherence4.

A bibliography may be requested at setuppsych@hushmail.com.

Please state in the subject line bibliography and this article title

in the text of the email.

MENTAL HEALTH AND

DIABETES (CONTINUED)

Medication Compliance : CBT-AD 24.3% greater compliance

than ETAU

Glucose Monitoring: CBT-AD 16.9% greater compliance than

ETAU

A1C: CBT-AD .63% lower than ETAU

Watch future issues of this newsletter for the

continued Mental Health and Diabetes series.

14

Submitted by: Reita Jones, RN, BSN, LDE, Kentucky Diabetes Prevention and Control Program (KDPCP)

KENTUCKY DIABETES COALITION EFFORTS

PROFILED AT APPALACHIAN CONFERENCE

Ashley Wilks, RN,

represented

Lawrence County

Health Department

and is pictured at

left.

Courtney Barnes,

Health Educator,

represented Estill

County Health

Department and Estill

County Diabetes

Coalition and is

pictured at left.

Debra Cox, RN,

BSN, represented

Estill County

Diabetes Coalition

and is pictured at

left.

Jamie Francis,

RN, ADN, BSW,

represented

Gateway District

Health Department

and is pictured at

left.

Jamie Lee, RN, CDE,

MLDE, represented

Lake Cumberland

District Health

Department and

Clinton County Health

Coalition and is

pictured at left.

Jennifer Wilson,

Health Educator,

represented

Johnson County

Health Department

and is pictured at

left.

Kentucky was represented at the “Appalachian Diabetes Coalitions Celebrating Success 2016” conference by numerous

presenters and participants.

The Centers for Disease Control and Prevention’s (CDC)

Diabetes Division has par tnered with the

Appalachian Regional Commission since 2001 to

address the high prevalence of diabetes in the thirteen

Appalachian states, particularly targeting areas

designated as “distressed counties”.

The project is directed and managed by Marshall University who

periodically awards grants to eligible communities forming or

strengthening community partnerships or coalitions to address

diabetes needs. This project has awarded numerous grants over the

last fifteen years — with many going to Kentucky communities.

Marshall University provides ongoing technical assistance, support,

trainings, and site visits.

The Appalachian Project grantees were invited to attend the

"“Appalachian Diabetes Coalitions Celebrating Success 2016” conference October 5-7 in Gatlinburg, Tennessee. Kentucky was

represented at the conference by several local diabetes coalitions and

by the Kentucky Diabetes Prevention and Control Program

(KDPCP). There were nine presentations on the conference agenda

by Kentucky coalition representatives to profile one or more of their

group’s projects. Kentucky presenters included Jennifer Wilson of

Johnson County; Ashley Wilks representing Lawrence County;

Christy Nuetzman of Clinton County; Brittany Martin of Pike

County, Jamie Francis representing Morgan County, Susan Kincaid

of Lee County, Debra Cox; and Courtney Barnes for Estill County;

Valerie Horn for Letcher County; and Jamie Lee, Janet Cowherd and

Vicky Albertson representing counties covered by the Lake

Cumberland District Health Department.

Kentucky Diabetes Coalition Efforts Include: Diabetes Prevention Program

Diabetes and Prediabetes Awareness Campaigns

Diabetes Self-Management Support Programs

Diabetes Screening Events

Physical Activity and Healthy Nutrition Classes and Events

Community, School and Senior Center Gardens

It was exciting and encouraging to hear all the good work coalitions

are doing to address diabetes-related needs in their communities.

Great work folks and we are proud to have you represent our

state at the conference!

15

Some hopeful trends related to obesity rates in 2-4

year olds were recently reported by the Centers for

Disease Control and Prevention (CDC). CDC’s News

and Notes, Division of Nutrition, Physical Activity,

and Obesity, reported a modest drop in obesity in

thirty-four states among 2 to 4 year old participants

in the special supplemental nutrition program for

Women, Infants, and Children (WIC). The percentage

of obesity among 2-4 years olds participating in WIC

decreased from 15.9 percent in 2010 to 14.5 percent in

2014.

These findings come from a new study from the Centers for Disease

Control and Prevention (CDC) and the United States Department of

Agriculture (USDA), published in the November 17th Morbidity and

Mortality Weekly Report.

In 2013-2014, the overall obesity prevalence in all children in the

US aged 2-5 was 9.4%. Childhood obesity is more prevalent among

lower-income young-children. These children are often

disproportionately affected by barriers such as access to healthy,

affordable foods and beverages and opportunities for low-cost

physical activity.

Authors noted several factors may have contributed to the drop

in obesity among WIC toddlers including:

WIC Food Package Redesign: In 2009, the WIC food

packages were redesigned to align with the U.S. Dietary

Guidelines for Americans.

National Awareness: Obesity programs and reports such as

Let’s Move! and the Institute of Medicine recommendations

for childhood obesity prevention policies raised awareness of

this issue.

Federal Support of State and Local Health

Agencies: CDC provided funding, training, and tools to all

50 states and D.C. to address childhood obesity prevention in

Early Care and Education settings.

Access the WIC Participant Characteristic Kentucky

data at:

https://nccd.cdc.gov/NPAO_DTM/

LocationSummary.aspx?state=Kentucky.

For more information about CDC’s childhood obesity

prevention efforts: www.cdc.gov/obesity/childhood.

OBESITY RATES DROP

AMONG 2 TO 4 YEAR OLD

WIC PARTICIPANTS

SPECIAL ISSUE EVIDENCED-BASED

DIABETES MANAGEMENT

Read the full issue at: http://www.ajmc.com/journals/

evidence-based-diabetes-management/2016/

December-2016

The American Association of Diabetes Educators (AADE) and the

American Journal of Managed Care (AJMC) recently published a

joint issue of Evidence-Based Diabetes Management, which

highlights the economics of diabetes and the need for more coverage

and payment for Diabetes Self-Management Education and Support

(DSMES) as well as diabetes prevention.

The special issue highlights the growing body of evidence

supporting DSMES as an effective disease management tool that

saves health systems money but is woefully underutilized. It argues

that more widespread use of DSMES will require that payers — both

public and private — rethink policies and payment structures.

In addition to coverage, the special issue features the following:

The accumulating evidence of the value of DSMES programs

accredited through AADE’s Diabetes Education Accreditation

Program.

The role of diabetes educators in helping Accountable Care

Organizations (ACOs) achieve the triple aim of improved

population health, improved patient experience and reduced

costs.

AADE’s role in scaling the National Diabetes Prevention

Program to the point that Medicare is prepared to pay for it

beginning January 1, 2018, as well as AADE’s

recommendations for reimbursement policy.

A focus on continued problems with Medicare’s Competitive

Bidding Program for diabetes testing supplies.

The

Journal,

pictured at left,

focuses on the

Cost and

Clinical

Effectiveness of

Diabetes Self-

Management

Education and

Support

(DSMES)

http://

www.ajmc.co

m/journals/

evidence-

based-

diabetes-

manage-

ment/2016/

December-

2016

16

JDRF 2017

KENTUCKY

NEW KY HOUSEHOLD

SHARPS DISPOSAL

FACT SHEET The Kentucky Department for Environmental Protection,

Division of Compliance Assistance (DCA) and the Kentucky

Department for Public Health, Diabetes Prevention and Control

Program (KDPCP) recently released a 2017 Waste Management

Fact Sheet for Household Sharps Disposal. This new fact sheet

provides safe options for the disposal of household sharps as

well as resources to obtain additional information.

Submitted by: Jeramie Irwin, Outreach and

Development Manager, JDRF Kentucky and

Southern Indiana Chapter, Louisville, KY

2017

JDRF

Upcoming

Events:

For 2017 JDRF Upcoming Events

Details — Visit:

http://www.jdrf.org/events/?location=Louisville%2C%20KY

Jeramie Irwin

The new 2017 Waste Management Fact Sheet for Household

Sharps Disposal, pictured above, was developed by Jon

Maybriar, Division Director of Waste Management (DWM),

Department for Environmental Protection, Energy and

Environment Cabinet (EEC) and Derek Bozzell with the Division

of Compliance Assistance in cooperation with the state staff of

the Kentucky Department for Public Health, Diabetes Prevention

and Control Program.

Consider including copies of this publication in your diabetes

education patient packets — Download at:

http://dca.ky.gov/DCA%20Resource%20Document%

20Library/SharpsDisposalFactSheet121416.pdf.

17

NEW NIDDK VIDEOS

ON MANAGING

DIABETES

ENDOCRINE SOCIETY

NEW GUIDELINES

HAVE YOU HEARD?

The National Institute of

Diabetes and Digestive and

Kidney Diseases (NIDDK)

recently released new videos on

managing diabetes. The

following topics are available:

The link between diabetes and heart disease

Living with diabetes and kidney disease

What to do when blood glucose gets too high or too low

How to cope with stress related to managing a chronic

health problem

In addition, a new animated video short, called “What is

Diabetes?” uses plain language to explain what diabetes is,

type 1 and type 2, potential complications and ways to

manage the disease.

For more information visit: http://ndep.nih.gov/resources/

diabetes-healthsense/?utm_source=newsletter_dk_health-

info-news&utm_medium=email&utm_campaign=october-

2016.

ADA ONLINE

RESOURCES

The Endocrine

Society recently

released a new

Clinical Practice

Guideline called

Diabetes Technology

— Continuous

Subcutaneous Insulin

Infusion Therapy and

Continuous Glucose

Monitoring in Adults.

Visit the ADA Patient Education Library website at:

http://professional.diabetes.org/search/site?f%5B0%

5D=im_field_dbp_ct%3A32&retain-filters=1

for access to patient education materials.

The American

Diabetes Association

(ADA) offers print-on-

demand patient

education handouts

that are free to

download and

distribute.

To download the new guideline visit: https://

www.endocrine.org/education-and-practice-management/

clinical-practice-guidelines.

NDEP TOOLKIT FOR

PROFESSIONALS

The National

Diabetes Education

Program (NDEP)

offers a toolkit for

professionals:

“Working Together to

Manage Diabetes: A

Toolkit for

Pharmacy, Podiatry,

Optometry, and

Dentistry (PPOD)”.

Download the toolkit at: http://www.cdc.gov/diabetes/

ndep/pdfs/ppod-guide.pdf.

For additional professional resources visit the NDEP

website: https://www.niddk.nih.gov/health-information/

health-communication-programs/ndep/Pages/index.aspx.

18

Earn 7 Complimentary CE

with Just Released AADE16

Symposia Recordings.

AADE is excited to offer five recorded sessions from AADE16 and the chance for members to

earn up to seven complimentary hours of CE.

Learn about the some of the latest diabetes education topics while earning complimentary CE from the

following sessions: Beginner’s Guide to Continuous CGM Earn 1 CE ($0 for members/$30 for nonmembers)

Optimizing Insulin Therapy Through Applied CGM Earn 1.5 CE ($0 for members/$45 for nonmembers)

Achieving Partnerships and Improving Outcomes in Your Diabetes Patients Earn 1.5 CE ($0 for members/$45 for

nonmembers)

Does the Shoe Fit? Matching the Right Insulin Combination to Individual Patients with T2DM Earn 1.5 CE ($0 for members/

$45 for nonmembers)

Constructing an Open and Shut Case for the Practical Application of New Insulin Formulations in T2DM Earn 1.5 CE

($0 for members/$45 for nonmembers)

More Free CE

These aren’t the only complimentary CE opportunities you have access to. AADE members have access to more than 20 hours of free CE.

Check out the full list of webinars and online courses that are available at no charge to members.

Register Online at: https://nf01.diabeteseducator.org/eweb/DynamicPage.aspx?WebCode=WebReplay&pager=10.

DIABETES EDUCATION OFFERINGS

Nurses, Dietitians, and Pharmacists earn

continuing education.

Certified Diabetes Educators earn hours

toward certification.

Contact: Julie Shapero or Janice Haile

julie.shapero@nkyhealth.org or janice.haile@ky.gov.

KADE Symposium 2017

Navigating the Maze of

Diabetes Care

May 19, 2017 Clarion Hotel

1950 Newtown Pike

Lexington, KY Registration Opens March 15th

For additional information:

KADENET.org

19

KENTUCKY DIABETES NETWORK (KDN)

MEETINGS SCHEDULED

The Kentucky Diabetes Network (KDN) is a network of

public and private providers striving to improve the

treatment and outcomes for Kentuckians with diabetes, to

promote early diagnosis, and ultimately to prevent the onset

of diabetes.

Anyone interested in improving diabetes outcomes in

Kentucky may join. Membership is free. A membership form

may be obtained at www.kydiabetes.net or by calling 502-564

-7996 (ask for diabetes program).

KDN 2017 Meeting Dates 10 am - 3 pm Eastern

June 16 Lexington — St. Joseph Office Park

September 15 Louisville — UL Shelbyville Campus

December 8 Frankfort — KY History Center

Register for a KDN Quarterly Meeting online:

www.kydiabetes.net

DECA DIABETES EDUCATOR

MEETINGS SCHEDULED

Diabetes Educators of the Cincinnati Area (DECA) (covers

Northern Kentucky) invites anyone interested in diabetes to

our programs. Please contact Susan Roszel at:

susan_roszel@trihealth.com 513-977-8942. Meetings are

held in Cincinnati four times per year at the Good Samaritan

Conference Center unless otherwise noted.

Registration 5:30 PM — Speaker 6 PM

1 Contact Hour

Fee for attendees who are not members of National AADE.

The Kentucky Association of Diabetes Educators (KADE),

(covers Lexington and Central Kentucky), meets quarterly

(time & location vary). For a schedule or more information, go

to www.kadenet.org or contact: Janey Wendschlag

JaneyCW57@gmail.com.

KADE Program March 21, 2017 5:30 pm

St. Joseph Office Park — Lexington, KY Dinner Provided

RSVP Needed For All Events / Programs

www.kadenet.org

KADE DIABETES EDUCATOR

MEETINGS SCHEDULED

GLADE DIABETES EDUCATOR

MEETINGS SCHEDULED

The Greater Louisville Association of Diabetes Educators

(GLADE), (covers Louisville and the surrounding area),

meets the second Tuesday every other month. Registration

required. For a meeting schedule or to register, contact Anne

Ries at 502-852-0253 anne.ries@louisville.edu or Christina

Weiermann at 502-879-8831 christina.weiermann@bhsi.com.

TRADE DIABETES EDUCATOR

MEETINGS SCHEDULED

The Tri-State Association of Diabetes Educators (TRADE),

(covers Western KY / Southern IN / Southeastern IL) meets

quarterly from 10 am – 2:15 pm CST with complimentary

lunch and continuing education. To register , email

Merritt Bates-Thomas at: merritt.bates-

thomas@grdhd.org or call 270-686-7747 ext. 3018.

TRADE 2017 Quarterly Programs / Meetings April 20, 2017

Owensboro Health — Owensboro, KY

July 20, 2017 The Medical Center — Bowling Green, KY

October 19, 2017 TRADE CONFERENCE Deaconess Hospital — Evansville, Indiana

Learn About CDC’s National Diabetes Prevention Program

http://www.cdc.gov/diabetes/prevention/index.htm

The Ohio River Regional Chapter of the American

Association of Clinical Endocrinologists (AACE) and the

Kentuckiana Endocrine Club (KEC) meet on a regular basis.

For a schedule of meetings, contact Vasti Broadstone, MD,

phone 812-949-5700 email joslin@FMHHS.com.

Register online at: https://www.aace.com/chapters/

Ohio-River-Region/Annual-Meeting/register/1

ENDOCRINOLOGISTS

MEETINGS SCHEDULED

Online

Registration

Now

Available

20

Editor

PO Box 309

Owensboro, KY 42302-0309

Presort Std.

US Postage

PAID

Owensboro, KY

42301

Permit # 120

NOTE: Editor reserves the right to edit for space, clarity, and accuracy.

Ohio River Regional Chapter

www.chfs.ky.gov/diabetes/

NEED A KY DIABETES RESOURCE?

Kentucky Diabetes Resource Directory Update your entry information

https://prd.chfs.ky.gov/KYDiabetesResources/

Local Networking Group of AADE

KENTUCKY ASSOCIATION

of DIABETES EDUCATORS

www.kadenet.org

joslin@fmhhs.com